MedTrace Logo

Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of Glabellar Lines

NCT01271452 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 224

Last updated 2019-01-29

Study results available
· View outcomes & findings →

Summary

This study will evaluate the safety and efficacy of two different types of botulinum toxin type A for the treatment of glabellar frown lines.

Conditions

  • Glabellar Lines

Interventions

BIOLOGICAL

botulinum toxin type A

20 units (total dose) botulinum toxin type A injected into glabellar region on Day 0

BIOLOGICAL

botulinum toxin type A

30 units (total dose) botulinum toxin type A injected into glabellar region on Day 0

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2011-01-31
Completion
2011-04-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01271452 on ClinicalTrials.gov